Recent 8-K filings for CYCN

• April 1, 2026, 7:59 PM ET M&A materiality 0.90 neutral item 1.01item 5.01item 5.02item 7.01item 9.01 ◈ Material Agreements

  Cyclerion to merge with Korsana in reverse merger; $380M PIPE; CVRs for legacy assets

  Merger: pre-Merger Korsana stockholders own ~1.5% of combined co (pre-PIPE); Cyclerion shareholders ~98.5%.

• February 17, 2026, 6:59 PM ET other material materiality 0.60 positive item 7.01item 9.01

  Cyclerion receives positive FDA feedback for CYC-126 Phase 2 POC study in TRD; remains on track for 2H 2026 initiation

  Received positive pre-IND written feedback from FDA supporting CYC-126 Phase 2 POC study design in treatment-resistant depression (TRD).

• January 6, 2026, 6:59 PM ET other material materiality 0.80 positive item 1.01item 7.01item 9.01 ◈ Material Agreements

  Cyclerion Therapeutics enters collaboration with Medsteer for CYC-126 anesthetic delivery system

  Cyclerion entered a Collaboration and Option Agreement with Medsteer for an anesthetic delivery system for treatment-resistant depression.

• December 1, 2025, 6:59 PM ET other material materiality 0.35 neutral item 8.01

  Cyclerion to receive $1M milestone if Akebia doses first patient in Phase 2 FSGS trial

  Akebia announced Phase 2 trial initiation for Praliciguat in FSGS; first patient dosing expected in 2026.

• September 23, 2025, 7:59 PM ET other material materiality 0.75 positive item 1.01item 7.01item 9.01

  Cyclerion licenses MIT tech for treatment-resistant depression; relaunches as neuropsychiatry company

  Entered exclusive worldwide license with MIT for neuropsychiatric technology; upfront payment nominal, milestones up to $4.4M plus low single-digit royalties.

• June 18, 2025, 7:59 PM ET other material materiality 0.15 neutral item 5.07item 9.01

  Cyclerion shareholders elect all six director nominees at annual meeting

  All six director nominees elected with >1.3M votes for each; broker non-votes 743,285.

• May 7, 2025, 7:59 PM ET other material materiality 0.55 neutral item 1.01item 9.01

  Cyclerion enters $20M ATM equity distribution agreement with Guggenheim

  Entered Sales Agreement with Guggenheim Securities for at-the-market offering of up to $20M of common stock.

• March 25, 2025, 7:59 PM ET other material materiality 0.30 neutral item 1.01item 3.02item 9.01

  Cyclerion raises $1.375M in private placement of 499,998 shares at $2.75/sh

  Sold 499,998 shares at $2.75 each to insiders Peter Hecht and Michael Higgins.

• December 17, 2024, 6:59 PM ET other material materiality 0.60 positive item 1.01item 7.01item 9.01

  Cyclerion secures $1.75M from praliciguat license amendment, signs olinciguat option deal

  Akebia to pay Cyclerion $1.25M by Dec 31, 2024, and $500k by Sep 30, 2025; assumes IP costs after Q1 2025.

• August 7, 2024, 7:59 PM ET leadership materiality 0.50 neutral item 7.01item 9.01

  Cyclerion promotes Regina Graul, Ph.D., to CEO and President

  Regina Graul, Ph.D., promoted to CEO, President, and Board member effective August 7, 2024.

• June 14, 2024, 7:59 PM ET other material materiality 0.15 neutral item 5.07item 9.01

  Cyclerion Therapeutics shareholders re-elect all five directors, ratify Ernst & Young as auditor

  Each of five director nominees (De Souza, Hecht, Hyman, Higgins, Katabi) elected with for votes ranging from 1,670,155 to 1,688,966.

• April 18, 2024, 7:59 PM ET other materiality 0.15 neutral item 8.01item 9.01

  Cyclerion sets 2024 annual meeting for June 14, 2024; record date April 17, 2024

  Annual meeting to be held on June 14, 2024 in virtual format.

Materiality & sentiment trend

Max materiality 0.90 · Median 0.53 · Most common event other_material

4 positive 0 negative 8 neutral

source · CYCN on sec.gov